Mr. Jeffrey Gahan

Mr. Jeffrey Gahan
Jeffrey Gahan, MD is an associate professor of urology at UT Southwestern Medical Center. He received his medical degree from Baylor College of Medicine and completed his urology and surgery residencies at the University of Miami/Jackson Memorial Hospital in Miami, Florida. He then completed his fellowship in Endourology and Minimally Invasive Surgery at UT Southwestern Medical Center. Dr. Gahan's primary research interests include the minimally invasive treatment of prostate cancer, renal carcinoma, and benign prostate enlargement. He is particularly interested in the applications of engineering technology to urology and works closely with engineers from SMU and the UT system. He published over 65 peer reviewed articles and has given presentations on his work at numerous national and international conferences. Clinically, he has been one of the pioneers developing a novel approach to prostate surgery dubbed the "Retzius Sparing Prostatectomy," which improves functional outcomes after prostate surgery. He also leads the implementation of a novel ablation technology, irreversible electroporation (nano knife), for the focal treatment of prostate cancer. In addition, he treats benign prostate enlargement using a number of technologies including holmium or thulium enucleation and Aquablation. Lasty, he specializes in the complex reconstruction of upper tract ureteral strictures using buccal mucosa I graft (tissue from the inner cheek) and ilea I interposition (segment small intestine).
Medical School:

Baylor College of Medicine


University of Miami


UT Southwestern Medical Center

All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Rx Only